Regeneron Reports Nearly Four-Year C-POST Data Show Sustained Survival Benefit for Adjuvant Libtayo in High-Risk CSCC
Regeneron (REGN) reported nearly 4-year data from the C-POST trial, showing a 37% reduction in death risk for high-risk CSCC patients treated with Libtayo. The data, presented at ESMO 2026, also confirmed sustained disease-free survival benefits, regardless of baseline MRD status. Libtayo has been approved for this indication in the U.S. and Europe.
How this was made
The 30-second read
Why it matters
The data provides the first mature overall‑survival evidence for Libtayo in the adjuvant setting, likely influencing analyst forecasts and stock valuation.
Market read
First disclosure of long‑term efficacy data for a marketed oncology drug; expected to move Regeneron stock and impact the immuno‑oncology sector.
What to watch
High crossover (88%) could mask true comparative efficacy; safety profile remains comparable to placebo.
Background
Regeneron announced the latest C‑POST trial results at the ESMO 2026 meeting, extending follow‑up to 44 months.
Ticker impact
Regeneron disclosed nearly four-year follow‑up data from the Phase 3 C‑POST trial showing a 37% reduction in overall‑mortality risk for adjuvant Libtayo in high‑risk CSCC.
likely upside as the market prices in the improved efficacy and potential expanded use of Libtayo.
First‑time disclosure of mature efficacy data for a marketed oncology drug; such data historically moves biotech stocks.
Market effects
Strengthens the broader immuno‑oncology sector, potentially benefiting peers with PD‑1 inhibitors.
U.S. biotech market may see modest gains as investors reassess oncology pipelines.
European and Asian markets with oncology exposure could see similar sentiment lifts.
Counterpoint
If crossover rates dilute the observed benefit, the data may be over‑interpreted, limiting upside.
Key entities
- companyRegeneron Pharmaceuticals, Inc.
Developer of Libtayo (cemiplimab) and issuer of REGN.
- drugLibtayo (cemiplimab)
PD‑1 inhibitor approved for high‑risk cutaneous squamous cell carcinoma.
